Literature DB >> 21123035

Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients.

P Bubber1, V Hartounian, G E Gibson, J P Blass.   

Abstract

Images of brain metabolism and measurements of activities of components of the electron transport chain support earlier studies that suggest that brain glucose oxidation is inherently abnormal in a significant proportion of persons with schizophrenia. Therefore, we measured the activities of enzymes of the tricarboxylic (TCA) cycle in dorsolateral-prefrontal-cortex from schizophrenia patients (N=13) and non-psychiatric disease controls (N=13): the pyruvate dehydrogenase complex (PDHC), citrate synthase (CS), aconitase, isocitrate dehydrogenase (ICDH), the alpha-ketoglutarate dehydrogenase complex (KGDHC), succinate thiokinase (STH), succinate dehydrogenase (SDH), fumarase and malate dehydrogenase (MDH). Activities of aconitase (18.4%, p<0.05), KGDHC (26%) and STH (28.2%, p<0.05), enzymes in the first half of the TCA cycle, were lower, but SDH (18.3%, p<0.05) and MDH (34%, p<0.005), enzymes in the second half, were higher than controls. PDHC, CS, ICDH and fumarase activities were unchanged. There were no significant correlations between enzymes of TCA cycle and cognitive function, age or choline acetyl transferase activity, except for aconitase activity which decreased slightly with age (r=0.55, p=003). The increased activities of dehydrogenases in the second half of the TCA cycle may reflect a compensatory response to reduced activities of enzymes in the first half. Such alterations in the components of TCA cycle are adequate to alter the rate of brain metabolism. These results are consistent with the imaging studies of hypometabolism in schizophrenia. They suggest that deficiencies in mitochondrial enzymes can be associated with mental disease that takes the form of schizophrenia.
Copyright © 2010 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123035      PMCID: PMC3033969          DOI: 10.1016/j.euroneuro.2010.10.007

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  43 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

Review 2.  Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment.

Authors:  Kedar N Prasad; William C Cole; K Che Prasad
Journal:  J Am Coll Nutr       Date:  2002-12       Impact factor: 3.169

Review 3.  Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine.

Authors:  Dorit Ben-Shachar
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

4.  N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia.

Authors:  S Dracheva; S A Marras; S L Elhakem; F R Kramer; K L Davis; V Haroutunian
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

5.  Inhibition of Krebs cycle enzymes by hydrogen peroxide: A key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress.

Authors:  L Tretter; V Adam-Vizi
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

Review 6.  The role of the metabolic lesion in Alzheimer's disease.

Authors:  John P Blass; Gary E Gibson; Siegfried Hoyer
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

7.  Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample.

Authors:  William S Stone; Stephen V Faraone; Jessica Su; Sarah I Tarbox; Paul Van Eerdewegh; Ming T Tsuang
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-05-15       Impact factor: 3.568

8.  Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.

Authors:  Martin R Gluck; Rohan G Thomas; Kenneth L Davis; Vahram Haroutunian
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

9.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress.

Authors:  S Prabakaran; J E Swatton; M M Ryan; S J Huffaker; J T-J Huang; J L Griffin; M Wayland; T Freeman; F Dudbridge; K S Lilley; N A Karp; S Hester; D Tkachev; M L Mimmack; R H Yolken; M J Webster; E F Torrey; S Bahn
Journal:  Mol Psychiatry       Date:  2004-07       Impact factor: 15.992

10.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

View more
  40 in total

1.  ¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis.

Authors:  Su-Wen Qi; Zhi-Guang Tu; Wu-Jian Peng; Lin-Xian Wang; Xin Ou-Yang; An-Ji Cai; Yong Dai
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

2.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia.

Authors:  Dan Shan; Daniel Mount; Stephen Moore; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-02-21       Impact factor: 4.939

3.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

4.  Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.

Authors:  Nima N Naseri; Hui Xu; Joseph Bonica; Jean Paul G Vonsattel; Etty P Cortes; Larry C Park; Jamshid Arjomand; Gary E Gibson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

Review 5.  Bioanalysis of eukaryotic organelles.

Authors:  Chad P Satori; Michelle M Henderson; Elyse A Krautkramer; Vratislav Kostal; Mark D Distefano; Mark M Distefano; Edgar A Arriaga
Journal:  Chem Rev       Date:  2013-04-10       Impact factor: 60.622

Review 6.  Mitochondrial dysfunction in schizophrenia: an evolutionary perspective.

Authors:  Vanessa F Gonçalves; Ana C Andreazza; James L Kennedy
Journal:  Hum Genet       Date:  2014-10-14       Impact factor: 4.132

Review 7.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

8.  Methylphenidate treatment leads to abnormalities on krebs cycle enzymes in the brain of young and adult rats.

Authors:  Gislaine Z Réus; Giselli Scaini; Camila B Furlanetto; Meline O S Morais; Isabela C Jeremias; Lis Mairá Mello-Santos; Karolina V Freitas; João Quevedo; Emilio L Streck
Journal:  Neurotox Res       Date:  2013-02-20       Impact factor: 3.911

9.  The negative impact of α-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation.

Authors:  Gergely Kiss; Csaba Konrad; Judit Doczi; Anatoly A Starkov; Hibiki Kawamata; Giovanni Manfredi; Steven F Zhang; Gary E Gibson; M Flint Beal; Vera Adam-Vizi; Christos Chinopoulos
Journal:  FASEB J       Date:  2013-03-08       Impact factor: 5.191

10.  An accurate method for the quantification of cytochrome C oxidase in tissue sections.

Authors:  Miguel Melendez-Ferro; Matthew W Rice; Rosalinda C Roberts; Emma Perez-Costas
Journal:  J Neurosci Methods       Date:  2013-01-30       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.